一文解读干眼症眼药水立他司特滴眼液

Introduction: (lifitegrast) was designed and developed by SARCODE Bioscience. In 2013, SARCODE Bioscience was acquired by Shire. Shire conducted subsequent development of lifitegrast and obtained approval from the US FDA for marketing in July 2016 under the trade name Xiidra. Litalast is the first new lymphocyte function-associated antigen 1 (LFA-1) antagonist drug approved by the FDA for the treatment of dry eye disease (EDE). It is also the only drug in the U.S. market that is prescribed as eye drops.

Effects of Ritalast Eye Drops

Ritalast, as a new small molecule integrin inhibitor, has shown significant effects in regulating the function of the immune system. It effectively reduces the level of inflammation mediated by T lymphocytes by precisely inhibiting the combination of lymphocyte function-related antigen 1 and intercellular adhesion molecule 1, providing a new idea for the treatment of inflammatory diseases. Ritalast's unique mechanism of action makes it highly efficient and targeted in controlling inflammation, and is expected to bring good news to many patients.

Effects of Lifitegrast Eye Drops

The efficacy evaluation results of 4 clinical trials showed that in the phase II clinical trial and the OPUS-1 trial, Lifitegrast could improve the physical signs (ICSS) of patients with mild to moderate DED with baseline symptoms; in the OPUS-2 and OPUS-3 trials, Lifitegrast improves symptoms (EDS, VAS) in patients with moderate to severe baseline symptoms of DED. Based on the above test results, it can be confirmed that 5% Lifitegrast eye drops are generally well tolerated, with mild and short-lived adverse reactions, and can significantly improve the signs and symptoms of DED patients.

Ritalast eye drops usage and dosage

When using Ritalast eye drops, specific steps need to be followed to ensure the safety and effectiveness of the medication. Apply 1 drop of Ritalast to each eye twice daily, approximately 12 hours apart, using a disposable container. Discard the container immediately after each eye is filled to avoid cross-contamination. Please remove contact lenses before administration and wait 15 minutes after administration before putting them back on. Please use it strictly in accordance with your doctor's instructions. If you have any discomfort or questions, please consult your doctor in time. Use medicine safely to protect eye health. The above information comes from the U.S. FDA instructions, and the patient’s final dosage needs to be determined by the doctor.